12
Participants
Start Date
July 17, 2023
Primary Completion Date
August 8, 2023
Study Completion Date
August 20, 2023
Hemay005 60 mg
"The eligible healthy adult participants will enter Single-dose Administration Period, receiving a single administration of Hemay005 tablets orally at a dose of 60 mg on Day 1 morning under fasted condition.~On Day 3, those participants will receive Hemay005 tablets at dose of 60 mg for 7 consecutive days, which will be administrated twice daily (BID) during Day 3 to Day 8 and only in the morning on Day 9."
Scientia Clinical Research Ltd, Randwick
Lead Sponsor
Collaborators (1)
Hemay Pharmaceutical PTY. LTD.
INDUSTRY
Ganzhou Hemay Pharmaceutical Co., Ltd
INDUSTRY